Tapentadol prolonged release for patients with multiple myeloma suffering from moderate-to-severe cancer pain due to bone disease

Flaminia Coluzzi, Robert B. Raffa, Joseph Pergolizzi, Alessandra Rocco, Pamela Locarini, Natalia Cenfra, Giuseppe Cimino, Consalvo Mattia

Research output: Contribution to journalArticle

Abstract

Context: Myeloma bone disease (MBD) is a devastating complication of multiple myeloma that leads to severe pain. Objectives: The aim of this study was to evaluate the efficacy and tolerability of tapentadol prolonged release (PR) in the management of patients with MBD suffering from moderate-to-severe cancer pain. Methods: A 12-week prospective study was carried out in 25 opioid-naïve MBD patients. Patients initially received twice-daily doses of tapentadol PR 50 mg. Doses were then managed to maintain adequate relief or dose-limiting toxicity. The following parameters were recorded at weekly intervals for 4 weeks, and then at weeks 8 and 12: pain, opioid-related adverse effects, use of other analgesics, DN4 (Douleur Neuropathique 4) score. Quality of life (SF-36 [36-item short-form health survey]) was measured at baseline and at final evaluation. Results: Of 25 patients, 22 completed the study. Pain intensity significantly decreased from baseline to all the week intervals (P

Original languageEnglish (US)
Pages (from-to)229-238
Number of pages10
JournalJournal of Pain Research
Volume8
DOIs
StatePublished - May 8 2015

Keywords

  • Bone
  • Multiple myeloma
  • Neuropathic pain
  • Opioids
  • Tapentadol

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Fingerprint Dive into the research topics of 'Tapentadol prolonged release for patients with multiple myeloma suffering from moderate-to-severe cancer pain due to bone disease'. Together they form a unique fingerprint.

  • Cite this

    Coluzzi, F., Raffa, R. B., Pergolizzi, J., Rocco, A., Locarini, P., Cenfra, N., Cimino, G., & Mattia, C. (2015). Tapentadol prolonged release for patients with multiple myeloma suffering from moderate-to-severe cancer pain due to bone disease. Journal of Pain Research, 8, 229-238. https://doi.org/10.2147/JPR.S83490